Watchlist Price Alert

ANI Pharmaceuticals Inc. (ANIP)

NASDAQ: ANIP · Real-Time Price · USD

60.00

0.47 (0.79%)

At close: May 16, 2025, 3:59 PM

59.95

-0.08%

After-hours: May 16, 2025, 04:40 PM EDT

0.79% (1D)

Bid	57.29
Market Cap	1.3B
Revenue (ttm)	674.07M
Net Income (ttm)	-21.05M
EPS (ttm)	-1.18
PE Ratio (ttm)	-50.85
Forward PE	8.53
Analyst	Buy

Ask	62.3
Volume	286,328
Avg. Volume (20D)	404,622
Open	59.60
Previous Close	59.53
Day's Range	59.06 - 60.47
52-Week Range	52.50 - 77.00
Beta	0.56

About ANIP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANIP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANIP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

ANI Pharmaceuticals has released their quartely earnings on May 9, 2025:

Revenue of $197.12M exceeds estimates by $16.43M, with 43.43% YoY growth.

EPS of 1.7 exceeds estimates by 1.76, with 40.50% YoY growth.

Why Price Moved

2 months ago

+13.39%

ANI Pharmaceuticals shares are trading higher afte... Unlock content with Pro Subscription

9 months ago

-9.92%

ANI Pharmaceuticals shares are trading lower after the company announced intent for a $250 million private offering of convertible senior notes.

News

6 days ago · zacks.com

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 week ago · seekingalpha.com

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Directo...

1 week ago · zacks.com

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

1 week ago · zacks.com

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates an...

1 week ago · zacks.com

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago.

1 week ago · seekingalpha.com

ANI Pharmaceuticals: A Short-Term Buying Opportunity

ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new f...

1 week ago · zacks.com

ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?

ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.

1 week ago · zacks.com

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2 weeks ago · zacks.com

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

3 Reasons Growth Investors Will Love ANI (ANIP)

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

Load More News